Advertisement

Role of b-Amyloid in the Pathophysiology of Alzheimer’s Disease and Cholinesterase Inhibition: Facing the Biological Complexity to Treat the Disease

  • Stefano Govoni
  • Michela Mazzucchelli
  • S. Carolina Lenzken
  • Emanuela Porrello
  • Cristina Lanni
  • Marco Racchi
Conference paper
Part of the Advances in Behavioral Biology book series (ABBI, volume 57)

Keywords

Amyloid Precursor Protein Cholinesterase Inhibitor AChE Inhibitor Amyloid Precursor Protein Processing Amyloid Precursor Protein Metabolism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

references

  1. Perry E, Ziabreva I, Perry R, et al. Absence of cholinergic deficits in “pure” vascular dementia Neurology 2005;64:132–133.Google Scholar
  2. Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease. J Neural Transm Suppl 2002;62:181–187.PubMedGoogle Scholar
  3. Racchi M, Govoni S. The pharmacology of amyloid precursor protein processing. Exp Gerontol 2003;38(1-2):145–157.PubMedCrossRefGoogle Scholar
  4. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992;258:304–307.PubMedCrossRefGoogle Scholar
  5. Racchi M, Mazzucchelli M, Porrello E, et al. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 2004;50(4):441–451.PubMedCrossRefGoogle Scholar
  6. Lahiri DK, Farlow MR, Nurnberger JL, Greig NH. Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures. Ann N Y Acad Sci 1997;826:416–421.PubMedCrossRefGoogle Scholar
  7. Racchi M, Sironi M, Caprera A, et al. Short- and long-term effect of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein. Mol Psychiatry 2001;6(5):520–528.PubMedCrossRefGoogle Scholar
  8. Mazzucchelli M, Porrello E, Villetti G, et al. Characterization of the effect of ganstigmine (CHF2819) on amyloid precursor protein metabolism in SH-SY5Y neuroblastoma cells. J Neural Transm 2003;110(8):935–947PubMedCrossRefGoogle Scholar
  9. Zimmermann M, Gardoni F, Marcello E, et al. Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J Neurochem 2004;90(6):1489–1499.PubMedCrossRefGoogle Scholar
  10. Pakaski M, Rakonczay Z, Fakla I, et al. In vitro effects of metrifonate on neuronal amyloid precursor protein processing and protein kinase C level. Brain Res 2000; 863:266–270.PubMedCrossRefGoogle Scholar
  11. Yogev-Falach M, Amit T, Bar-Am O, et al. Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 2002;16(12):1674–1676.PubMedGoogle Scholar
  12. Shaw KT, Utsuki T, Rogers J, et al. Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci U S A 2001;98(13):7605–7610.PubMedCrossRefGoogle Scholar
  13. Lanni C, Mazzucchelli M, Porrello E, et al. Differential involvement of protein kinase C alpha and epsilon in the regulated secretion of soluble amyloid precursor protein. Eur J Biochem 2004;271(14):3068–3075.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Stefano Govoni
    • 1
  • Michela Mazzucchelli
  • S. Carolina Lenzken
  • Emanuela Porrello
  • Cristina Lanni
  • Marco Racchi
  1. 1.Department of Experimental and Applied PharmacologyCentre of Excellence in Applied BiologyItaly

Personalised recommendations